Replimune Group (REPL) Competitors

Replimune Group logo
$13.94 -0.12 (-0.85%)
Closing price 02/7/2025 04:00 PM Eastern
Extended Trading
$13.97 +0.03 (+0.22%)
As of 02/7/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REPL vs. RYTM, CRNX, APLS, IMVT, VKTX, ACLX, DNLI, TWST, ACAD, and XENE

Should you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Rhythm Pharmaceuticals (RYTM), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Viking Therapeutics (VKTX), Arcellx (ACLX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

Replimune Group vs.

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.

Rhythm Pharmaceuticals has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Replimune Group has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Replimune Group's return on equity of -53.12% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-230.07% -367.36% -77.47%
Replimune Group N/A -53.12%-41.49%

Rhythm Pharmaceuticals has higher revenue and earnings than Replimune Group. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$77.43M46.97-$184.68M-$4.33-13.67
Replimune GroupN/AN/A-$215.79M-$3.05-4.57

92.5% of Replimune Group shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals presently has a consensus target price of $68.09, indicating a potential upside of 15.06%. Replimune Group has a consensus target price of $19.14, indicating a potential upside of 37.32%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91
Replimune Group
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Rhythm Pharmaceuticals received 129 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 67.12% of users gave Rhythm Pharmaceuticals an outperform vote while only 63.74% of users gave Replimune Group an outperform vote.

CompanyUnderperformOutperform
Rhythm PharmaceuticalsOutperform Votes
296
67.12%
Underperform Votes
145
32.88%
Replimune GroupOutperform Votes
167
63.74%
Underperform Votes
95
36.26%

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Replimune Group. MarketBeat recorded 12 mentions for Rhythm Pharmaceuticals and 2 mentions for Replimune Group. Rhythm Pharmaceuticals' average media sentiment score of 0.33 beat Replimune Group's score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Replimune Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Replimune Group beats Rhythm Pharmaceuticals on 10 of the 18 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REPL vs. The Competition

MetricReplimune GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$961.95M$3.09B$5.75B$9.10B
Dividend YieldN/A1.79%5.30%4.00%
P/E Ratio-4.5746.3089.2219.39
Price / SalesN/A439.721,022.5981.33
Price / CashN/A192.7646.1438.79
Price / Book2.294.075.134.75
Net Income-$215.79M-$41.02M$114.53M$222.93M
7 Day Performance-0.29%0.41%-0.47%0.14%
1 Month Performance20.90%-3.10%0.11%-0.13%
1 Year Performance80.57%-2.37%23.87%21.23%

Replimune Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REPL
Replimune Group
3.9556 of 5 stars
$13.94
-0.9%
$19.14
+37.3%
+87.9%$961.95MN/A-4.57210Upcoming Earnings
RYTM
Rhythm Pharmaceuticals
3.6885 of 5 stars
$59.41
0.0%
$68.09
+14.6%
+23.8%$3.65B$77.43M-13.72140Insider Trade
Analyst Revision
CRNX
Crinetics Pharmaceuticals
4.3304 of 5 stars
$38.84
-3.6%
$72.64
+87.0%
-2.1%$3.60B$1.04M-10.41210Analyst Forecast
Insider Trade
Analyst Revision
News Coverage
APLS
Apellis Pharmaceuticals
4.388 of 5 stars
$28.53
-1.7%
$46.71
+63.7%
-55.9%$3.55B$715.22M-14.05770Gap Down
IMVT
Immunovant
2.8479 of 5 stars
$20.84
-4.1%
$47.00
+125.5%
-42.1%$3.54BN/A-9.39120Earnings Report
Upcoming Earnings
Analyst Forecast
Analyst Revision
News Coverage
VKTX
Viking Therapeutics
4.4705 of 5 stars
$31.48
-3.9%
$106.75
+239.2%
+33.0%$3.51BN/A-33.8420Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
ACLX
Arcellx
2.7672 of 5 stars
$64.73
-5.0%
$105.93
+63.7%
+4.8%$3.50B$110.32M-91.1680
DNLI
Denali Therapeutics
4.2867 of 5 stars
$21.88
-6.1%
$38.00
+73.7%
+31.3%$3.15B$330.53M-7.93430
TWST
Twist Bioscience
2.9318 of 5 stars
$52.72
+0.7%
$51.90
-1.5%
+49.6%$3.13B$312.97M-14.64990Earnings Report
Analyst Forecast
Insider Trade
Analyst Revision
News Coverage
ACAD
ACADIA Pharmaceuticals
3.4895 of 5 stars
$18.51
-0.8%
$25.25
+36.4%
-26.4%$3.08B$726.44M23.72510Gap Down
XENE
Xenon Pharmaceuticals
2.6186 of 5 stars
$39.58
-1.0%
$56.00
+41.5%
-16.8%$3.02B$9.43M-14.04210Options Volume
News Coverage

Related Companies and Tools


This page (NASDAQ:REPL) was last updated on 2/8/2025 by MarketBeat.com Staff
From Our Partners